EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pharmacovigilance Insights Into Immune Checkpoint Inhibitor‐Induced Risk of Paraneoplastic Syndrome: A Large‐Scale Real World Study

Bufu Tang iD, Xin Song, Yiting Sun, Juncheng Wan, Wenlu Hu, Yifei Ma, Yihang Lin, Jian Zhang iD, Yiou Wang, Hongyang Feng, Peng Luo iD, Dandan Guo iD und 1 weitere

CNS Neuroscience & Therapeutics · 2026

DOI: 10.1002/cns.70747 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2026. Verfasst von Bufu Tang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Interventional Radiology, Zhongshan Hospital, Shanghai Institute of Medical Imaging, National Clinical Research Center of Interventiona…. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Pharmacovigilance, Paraneoplastic Syndromes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Scientific Research Development Fund of Zhongshan Hospital, Fudan University, National Natural Science Foundation of China, Shanghai Innovative Medical Device Product Application Demonstration Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune checkpoint inhibitor (ICI)‐associated paraneoplastic syndromes (PS) represent a rare but potentially life‐threatening adverse event. Despite the widespread use of ICIs in cancer treatment, the clinical characteristics and risk profiles of PS across different treatment regimens remain incompletely characterized.

Methods

We analyzed FAERS data (Jan 2011–Jun 2024) to identify PS cases potentially related to ICI use. Reporting odds ratios (RORs) were calculated to evaluate safety signals. Clinical features, time‐to‐onset, and outcomes were analyzed across different ICI regimens.

Results

Among 162,493 ICI‐associated adverse event reports, 179 PS cases were identified. Disproportionate reporting of PS was observed with PD‐1 inhibitors (ROR 21.77, 95% CI 16.36–28.97), PD‐L1 inhibitors (ROR 23.33, 95% CI 14.13–38.41), nivolumab plus ipilimumab (ROR 24.21, 95% CI 18.07–32.42), and durvalumab plus tremelimumab (ROR 24.55, 95% CI 18.73–32.79). PS onset showed a bimodal distribution, with a median time to onset of 6 days, where 42.31% occurring within 30 days and 23.08% after 360 days of treatment initiation. Combination therapy, particularly durvalumab plus tremelimumab, was associated with higher rates of severe outcomes (27.8%). In patients with PS related to ICI therapy, those with lung malignancies are the most commonly represented group.

Conclusions

This analysis reveals distinct temporal patterns and safety signals of ICI‐associated PS, with higher reporting rates and severity in combination therapy. These findings provide important insights for clinical monitoring strategies and highlight the need for increased vigilance during specific risk windows, particularly in patients receiving combination therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsPharmacovigilanceParaneoplastic SyndromesHumansFemaleMaleMiddle AgedAgedAdultAged, 80 and overRetrospective Studies

Stichwörter der Autor:innen

FAERSdisproportionality analysisdrug safetyimmune checkpoint inhibitorparaneoplastic syndromespharmacovigilance

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Interventional Radiology, Zhongshan Hospital, Shanghai Institute of Medical Imaging, National Clinical Research Center of Interventional Medicine, Fudan University, Shanghai, China.
  • Department of Emergency, Shenzhen Bao'an District Songgang People's Hospital, Shenzhen, Guangdong, China.
  • China Medical University, Shenyang, China.
  • Department of Oncology, First Affiliated Hospital of Dalian Medical University, Dalian, China.
  • Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.

ORCID-Profile: Bufu Tang, Jian Zhang, Peng Luo, Dandan Guo, Xudong Qu

Förderung

  • Scientific Research Development Fund of Zhongshan Hospital, Fudan University
  • National Natural Science Foundation of China
  • Shanghai Innovative Medical Device Product Application Demonstration Project
  • National Key Research and Development Program of China
  • National Key Research and Development Program
  • Shanghai Innovative Medical Devices and Pharmaceuticals Application Demonstration Project
  • Shanghai Innovative Medical Devices Application Demonstration Project
  • Scientific Research Development Fund of Zhongshan Hospital Affiliated to Fudan University

Zitieren

APA

Tang, B., Song, X., Sun, Y., Wan, J., Hu, W., Ma, Y., Lin, Y., Zhang, J., Wang, Y., Feng, H., Luo, P., Guo, D., & Qu, X. (2026). Pharmacovigilance Insights Into Immune Checkpoint Inhibitor‐Induced Risk of Paraneoplastic Syndrome: A Large‐Scale Real World Study. CNS Neuroscience & Therapeutics. https://doi.org/10.1002/cns.70747

Vancouver

Tang B, Song X, Sun Y, Wan J, Hu W, Ma Y, et al. Pharmacovigilance Insights Into Immune Checkpoint Inhibitor‐Induced Risk of Paraneoplastic Syndrome: A Large‐Scale Real World Study. CNS Neuroscience & Therapeutics. 2026. doi:10.1002/cns.70747

BibTeX
@article{Tang2026,
  author = {Tang, Bufu and Song, Xin and Sun, Yiting and Wan, Juncheng and Hu, Wenlu and Ma, Yifei and Lin, Yihang and Zhang, Jian and Wang, Yiou and Feng, Hongyang and Luo, Peng and Guo, Dandan and Qu, Xudong},
  title = {Pharmacovigilance Insights Into Immune Checkpoint Inhibitor‐Induced Risk of Paraneoplastic Syndrome: A Large‐Scale Real World Study},
  journal = {CNS Neuroscience & Therapeutics},
  year = {2026},
  doi = {10.1002/cns.70747}
}
Kostenlos starten →